Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | MAOB | P27338 | 1/20 | 0.83 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294761 | 0.98 | DPP4 (0.96) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6809143 | 0.98 | DPP4 (0.96) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3520274 | 0.96 | DPP4 (0.92) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL294970 | 0.95 | DPP4 (0.91) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Water SCHEMBL7260926 | 0.93 | DPP4 (0.88) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6809124 | 0.93 | DPP4 (0.88) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL1492704 | 0.91 | MAOB (1.00) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6813615 | 0.88 | MAOB (0.95) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL3516310 | 0.86 | SLC6A3 (1.00) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Carbamic Acid SCHEMBL10009301 | 0.86 | DPP4 (0.75) | DPP4MAOAMAOBTAAR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | claimed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4038065-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2022-08-10 | — | — | EP | disclosed |
| US-20220204423-A1 | CASHEW NUT SHELL LIQUID BASED SUBSTITUTED CYCLOHEXENE DERIVATIVES AND USES THEREOF | CARDOLITE CORPORATION | 2022-06-30 | — | — | US | disclosed |
| US-4755594-A | N6 -substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| EP-0232813-A2 | N6-substituted Adenosines | WARNER-LAMBERT COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0010401-B1 | NOVEL (1-SUBSTITUTED) CYCLOALKYLMETHYL-ISOTHIOCYANATES, A PROCESS FOR THEIR PREPARATION, COMPOSITIONS COMPRISING THEM, AND THEIR USE AS PESTICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-05-05 | — | — | EP | disclosed |
| US-4216217-A | FUNGICIDES, INSECTICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | DPP4 1536/4885MAOA 1184/4885MAOB 518/4885 |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | DPP4 2807/4885MAOA 2812/4885MAOB 3262/4885 |
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TYMP, HPRT1, DPYD | DPP4 1372/4885MAOA 2368/4885MAOB 470/4885 |
| US-20220204423-A1 | CASHEW NUT SHELL LIQUID BASED SUBSTITUTED CYCLOHEXENE DERIVATIVES AND USES THEREOF | HTR3D, DNER, TAS1R3 | DPP4 1369/4885MAOA 1920/4885MAOB 2420/4885 |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | DPP4 152/4885MAOA 1717/4885MAOB 1853/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | DPP4 1890/4885MAOA 1105/4885MAOB 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.